Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Aura Biosciences Inc (AURA)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and Aura Biosciences Inc (AURA – Research Report) with bullish sentiments.
Eli Lilly & Co (LLY)
In a report released today, Carter Gould from Barclays assigned a Buy rating to Eli Lilly & Co, with a price target of $1025.00. The company’s shares closed last Monday at $914.05, close to its 52-week high of $972.53.
According to TipRanks.com, Gould is a 5-star analyst with an average return of 11.7% and a 55.6% success rate. Gould covers the Healthcare sector, focusing on stocks such as Barinthus Biotherapeutics, Bristol-Myers Squibb, and Travere Therapeutics.
Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $1049.18, which is a 13.9% upside from current levels. In a report issued on September 13, Citi also initiated coverage with a Buy rating on the stock with a $1060.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Aura Biosciences Inc (AURA)
In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Aura Biosciences Inc, with a price target of $23.00. The company’s shares closed last Monday at $9.09.
According to TipRanks.com, Wolleben is a 4-star analyst with an average return of 8.1% and a 45.6% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Sagimet Biosciences, Inc. Class A, and DBV Technologies SA – American.
Currently, the analyst consensus on Aura Biosciences Inc is a Strong Buy with an average price target of $21.33, representing a 122.2% upside. In a report issued on September 9, LifeSci Capital also maintained a Buy rating on the stock with a $23.00 price target.
Read More on LLY: